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MACROPHAGES AND MICROGLIA IN GLIOBLASTOMA 
CHRISTOPHER FIGUEROA 
 
ABSTRACT 
Glioblastoma is the most common and most deadly form of brain cancer. With treatment, 
expected survival time after diagnosis is 15 months and the disease presents with 
universal morbidity. Current therapies include surgery, radiation, and chemotherapy. One 
of the current fields of interest for glioblastoma research is in immunotherapy and 
specifically tumor-associated macrophages (TAMs). Normally, macrophages in an 
infection or disease state work to degrade and digest pathogens and cancer cells. 
However, in glioblastoma, current evidence points to TAMs as active tumor-supporters 
and immunosuppressants. While the field is still relatively in its infancy, much is known 
about TAMs and their interactions with other immune cells and with cancer cells. This 
paper elucidates all the different aspects in which TAMs work to support GBM cancer 
cells and how they encourage tumor growth, progression, and migration. This review 
consolidates the pertinent information known on how TAMs are recruited, how they 
contribute to angiogenesis, how they promote tumor migration, how they interact with T 
cells, and how they become polarized to become tumor-supportive macrophages and 
suggests approaches for future research given this knowledge. 
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INTRODUCTION 
 
Glioblastoma is the most common primary brain tumor and the most aggressive. It 
accounts for nearly 15% of all brain tumors and has a median survival rate of 15 
months.(Alifieris & Trafalis, 2015) While there is no cure for the disease, standard 
treatment for patients is a combination of radiation therapy and temozolomide along with 
surgical resection.(Alifieris & Trafalis, 2015) Within the tumor population are a subset of 
cells that are self-renewing and stem cell-like, leading to the hypothesis that these glioma 
stem cells (GSCs) are what is responsible for the initial formation of the tumor and its 
resistance to all therapies.(Lathia, Mack, Mulkearns-Hubert, Valentim, & Rich, 2015) 
Also found in the tumor microenvironment are immune cells, with a particularly 
abundant amount of tumor-associated macrophages and microglia (TAMs).(Yang, Han, 
Kaur, Crane, & Parsa, 2010) Macrophages are myelopoietic in origin and belong to the 
monocyte lineage. They are found ubiquitously throughout all different tissues and 
function to digest pathogens and cancer cells via phagocytosis. Microglia are a special 
subset of macrophages that are found only in the central nervous system (CNS) and act as 
glial cells (CNS cells that support neurons) in the CNS.(Ginhoux, Lim, Hoeffel, Low, & 
Huber, 2013) Normally, the blood-brain barrier (BBB) prevents peripheral immune cells 
from entering the CNS but during the diseased state of glioblastoma, the BBB breaks 
down and bone marrow-derived macrophages are found within the tumor population in 
the brain.(Yang et al., 2010) Targeting these immune cells instead of the tumor cells 
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themselves has recently garnered a lot of interest since these immune cells are much less 
susceptible to mutations and acquired resistance than the tumor cells. 
 
Traditionally, TAMs fall under two general categories: M1 or M2. M1 macrophages react 
in an inflammatory manner and are actively involved in phagocytosis to dispose of 
pathogens or aberrant cells (Figure 1). M1 TAMs are typically activated by interferon-
gamma (IFN-gamma) and lipopolysaccharide (LPS) and tend to secrete high levels of IL-
12 while almost no IL-10 and some IL-6.(Eder & Kalman, 2015) However, in GBM there 
is a high expression level of TGF-beta, which inhibits expression of IFN-gamma, making 
it less likely for any TAMs to be directed towards an M1 phenotype.(Eder & Kalman, 
2015) M2 macrophages typically are directed to initiate the process of tissue repair and to 
silence any remaining inflammation.  
 
M2 TAMs respond to IL-4, IL-10, and IL-13 in tumor microenvironment and 
secrete IL-10 while almost no IL-12.(Eder & Kalman, 2015) In tumors, the M1 TAMs 
play a tumor-suppressive role while the M2 TAMs serve an anti-inflammatory, tumor-
supportive role.(Zhou et al., 2015) However, the primary consensus that M1 phenotype 
plays a tumor-suppressive role has been challenged, by studies that showed that 
upregulated IL1-beta, which is typically an M1 marker, actually supported tumor 
growth.(Feng et al., 2015) Further research, however, is needed to validate this 
hypothesis. In glioblastoma, the majority of TAMs display a tumor-supportive, M2 
profile with a higher density of M2 TAMs correlating with a greater proliferation of 
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GBM tumor cells.(Komohara, Ohnishi, Kuratsu, & Takeya, 2008) Since M1 TAMs are 
highly anti-tumor and pro-inflammatory, much research in the field of glioblastoma 
immunology is focused on reverting M2 TAMs back to an anti-tumor M1 phenotype.  
 
Figure 1: Summary of M1 and M2 Activators and Effectors. Figure taken from (Li et 
al., 2012)(W. Li & Graeber, 2012) 
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TAM RECRUITMENT 
 
Microglia are the resident immune cells of the CNS, and along with macrophages, are 
found abundantly in tumors in the CNS.(Anna Carolina Carvalho da Fonseca et al., 2016) 
Approximately 30-50% of the tumor mass is composed of these microglia and 
macrophages.(Hambardzumyan, Gutmann, & Kettenmann, 2016) One study found that 
the majority of TAMs in glioblastoma are in fact macrophages derived from peripheral 
blood, as opposed to resident microglia.(Zhou et al., 2015) Current evidence points 
toward the hypothesis that these TAMs are in fact suppressing immunity and thereby 
allowing for tumor proliferation.(Anna Carolina Carvalho da Fonseca et al., 2016) The 
primary cytokines that GBM cells use to recruit and silence the anti-tumor effects of 
TAMs are CCL-2, periostin, HGF/SF, VEGF, macrophage inhibitory cytokine-1 (MIC-
1), colony stimulatory factor (CSF), transforming growth factor (TGF-beta), and GDNF 
(Figure 2).(Wu et al., 2010) (Platten et al., 2003) (W. Li & Graeber, 2012) When GBM 
cells secrete TGF-beta, it causes a wide array of immuno-suppressive effects.(W. Li & 
Graeber, 2012) Pertinently, it decreases the expression of MHC II complex on TAMs and 
suppresses their phagocytic abilities.(W. Li & Graeber, 2012) Hepatocyte growth 
factor/scatter factor (HGF/SF) secreted from GBM cells attracts microglia by binding to 
its receptor tyrosine kinase c-Met.(W. Li & Graeber, 2012) Although VEGF is normally 
thought of in the realm of promoting angiogenesis, it also attracts TAMs when secreted 
by GBM cells.(Forstreuter, Lucius, & Mentlein, 2002) When VEGF is overexpressed 
more than in normal GBM cell lines, there is a major increase in TAM infiltration as 
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compared to normal GBM microenvironment, showing that VEGF may in fact be more 
important for chemotaxis than previously thought.(Kerber et al., 2008) When GBM cells 
secrete chemokine ligand 2 (CCL-2 - also known as MCP-1), CCL2 binds to the MCP-1 
receptor called CCR2 on astrocytes, microglia, and endothelial cells.(Platten et al., 2003) 
(Yang et al., 2010) When this binding occurs with microglia, the microglia release IL-6. 
Elevated IL-6 is associated with tumor progression and poor patient prognosis.(Wang et 
al., 2009) One effect of the elevated IL-6 levels is that microglia are induced to release 
MMP-2 (a matrix metalloproteinase), which allows for tumor cells to migrate far 
easier.(Anna Carolina Carvalho da Fonseca et al., 2016) Another study, however, has 
found that MCP-3 (CCL7) rather than MCP-1 is more responsible for TAM infiltration 
into the tumor but further studies are needed to conclude which of the two is more crucial 
for recruiting TAMs.(Okada et al., 2009) 
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Figure 2: Summary of Tumor-Supportive and Tumor-Suppressive Cytokines in 
GBM. Figure taken from (Zhu et al., 2011)(V. F. Zhu, Yang, LeBrun, & Li, 2012) 
 
Another means by which these TAMs are recruited is by release of periostin from 
GSCs.(Zhou et al., 2015) Periostin is a secreted cell adhesion protein that can serve as a 
ligand for integrins found on cancer cells, including GBM.(Cavaleri & Monaco, 2015) 
The periostin level highly correlates with the TAM density in the tumor population and 
when periostin is inhibited, there is a marked reduction in tumor growth and a decrease in 
TAM density.(Zhou et al., 2015) It has been shown that silencing periostin leads to a 
dramatic reduction in the number of M2 TAMs while increasing the relative fraction of 
M1 TAMs, thereby supporting the theory that M2 TAMs are tumor-supportive.(Zhou et 
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al., 2015) It has also been shown that a co-transplantation of M2 TAMs with GSCs in 
mice accelerated tumor growth and decreased survival in mice as compared to GSC 
implantation alone, thereby providing further evidence of the tumor-supportive M2 TAM 
role in tumor progression.(Zhou et al., 2015) 
 
Another way that GBM cells recruit microglia is by the secretion of glial cell line-derived 
neurotrophic factor (GDNF).(Ku et al., 2013) Although GDNF is essential for neuronal 
survival, high levels of GDNF from GBM cells cause microglial attraction to tumor 
site.(Ku et al., 2013) When GBM media is depleted of GDNF and when GBM cells that 
have a GDNF knockdown are inserted into mice, tumor sizes are smaller and there is 
much less microglial infiltration.(Ku et al., 2013) 
 
The most common genetic alteration seen in glioblastoma is the mutation for epidermal 
growth factor receptor (EGFR).(Taylor, Furnari, & Cavenee, 2012) When EGFR is 
blocked by the inhibitor gefitinib, there is a strong reduction in the invasion of TAMs at 
the tumor site with minimum effect on glioblastoma invasion, implying that EGFR 
signaling pathway increases TAM recruitment.(Coniglio et al., 2012) 
 
Another chemoattractant for TAMs is the granulocyte-macrophage colony-stimulating 
factor (GM-CSF).(Sielska et al., 2013) When GM-CSF is knocked down, microglia 
invasion decreases and there is a significantly smaller tumor as compared to those 
without the knockdown.(Sielska et al., 2013) A knockdown of GM-CSF also causes 
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tumor-bearing mice to live longer and decreases angiogenesis in tumors.(Sielska et al., 
2013) The knockdown of GM-CSF causes an increase in the pro-inflammatory cytokine 
IL-6 and reverts TAMs to an M1 anti-tumor phenotype.(Sielska et al., 2013) This shows 
that GM-CSF plays a role in both recruiting TAMs and polarizing TAMs toward an M2 
phenotype.(Sielska et al., 2013) The gene that encodes GM-CSF is called CSF2 and is 
overexpressed in GBM patients and is inversely correlated with patient survival, thereby 
making this an even more attractive therapeutic target.(Sielska et al., 2013) 
 
Glioma cells will also recruit microglia by releasing colony stimulating factor-1 (CSF-1) 
(Figure 4).(Coniglio et al., 2012) (Pyonteck et al., 2013) When the CSF-1 receptor (CSF-
1R) on the microglial is blocked, there is a decrease in tumor progression and an 
increased survival rate in tumor-bearing mice.(Coniglio et al., 2012) (Pyonteck et al., 
2013) Although there is a marked reduction in M2 TAMs when cells are treated with a 
CSF-1R inhibitor, there is no evident TAM depletion because glioma cells are able to 
circumnavigate the CSF-1 pathway for survival and instead rely on GM-CSF, IFN-
gamma, and CXCL10 to promote macrophage survival. Although there is no immediately 
apparent TAM depletion upon treatment with a CSF-1R inhibitor, there is still marked 
tumor-suppression because the inhibitor is able to alter the phenotype of the M2 TAM 
into a more tumor-suppressive, phagocytic role.(Pyonteck et al., 2013) However, the 
efficacy of the CSF-1R inhibitor is potent yet ephemeral, with tumor cells eventually 
acquiring resistance to the inhibitor.(Quail et al., 2016) It has been shown that these 
tumor cells acquire resistance to CSF-1R inhibitors by relying on macrophage-derived 
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insulin-like growth factor-1 (IGF-1) to increase its own phosphatidylinositol 3-kinase 
(PI3K) pathway activity.(Quail et al., 2016) The increased levels of IGF-1 coming from 
TAMs are in part due to the response to IL-4 supplied by T cells (Figure 3).(Quail et al., 
2016) This IGF-1 is then able to support tumor growth by activating IGF-1R and PI3K 
pathways in tumor cells.(Quail et al., 2016) Combining a CSF-1R inhibitor along with an 
IGF-1R inhibitor or a PI3K inhibitor significantly increase survival in vivo as compared 
to treatment with CSF-1R inhibitor alone.(Quail et al., 2016) 
 
 
Figure 3: Resistance of CSF-1R inhibition in glioma. Figure taken from (Quail et al., 
2016) 
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Figure 4: Interactions Between Glioma Cells and Microglia. An increase in CSF-1 
secretion by glioma cells tends to recruit microglia and shift microglia to M2 phenotype. 
Taken from (Kim et al., 2016)(Kim, Jeon, & Othmer, 2017) 
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TAMS AND TUMOR MOTILITY 
 
Another major tumor-supportive function that TAMs provide is that they assist GBM 
cells in traveling to other parts of the brain, which is one of the primary reasons for 
GBM’s universal morbidity. The main method by which GBM cells induce TAMs to aid 
them in migration is by causing TAMs to release matrix metalloproteinases (MMPs). 
These MMPs degrade the extracellular matrix and allow the GBM cells to move more 
freely throughout the brain. Current research on TAM-induced GBM migration has been 
to inhibit these MMPs and prevent their secretion. 
 
The Na+/H+ exchanger isoform 1 (NHE1) has been found to be up-regulated in both 
glioma cells and the microglia with which it interacts.(W. Zhu et al., 2016) When NHE1 
is inhibited with a small molecule or a small-interfering RNA (siRNA), however, both 
microglia activation and tumor progression reduce.(W. Zhu et al., 2016) This NHE1 
protein on microglia is thought to be in part responsible for aiding glioma cells migrate 
by releasing MMPs, which degrade parts of the extracellular matrix to allow for easier 
passage of cells.(W. Zhu et al., 2016) When NHE1 is inhibited in microglia, there is a 
decreased enzymatic level of MMP-9 implying that the NHE1 exchanger is needed in 
order to release functional MMPs and promote tumor progression.(W. Zhu et al., 2016) 
 
One group showed that when microglia release stress-inducible protein (STI1), it 
promotes tumor proliferation and causes GBM cells to migrate in vitro.(A. C. C. da 
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Fonseca et al., 2012) This effect was reversed when STI1 was immuno-depleted from the 
microglia-conditioned media.(A. C. C. da Fonseca et al., 2012) They also showed that 
when they added STI1 antibody to the media, it significantly decreased the activity of a 
MMP-9.(A. C. C. da Fonseca et al., 2012) It is thought that the GBM cells use this STI1 
to aide in their migration by increasing the activity of MMP-9.(A. C. C. da Fonseca et al., 
2012) This same group also used a mouse model to show that as the tumor progressed 
and proliferated, there was an increase in STI1 expression in the surrounding microglia, 
macrophages, and lymphocytes.(A. C. C. da Fonseca et al., 2012) Another group showed 
that when microglia were treated with an inhibitor (minocycline), the levels of MMP-9 in 
microglia decreased, and as a result inhibited tumor migration.(Hu et al., 2014)  
 
It has also been demonstrated that GBM cells can induce the microglia to upregulate a 
membrane-type-1 matrix metalloproteinase (MT1-MMP), which also allows GBM cells 
to migrate.(Vinnakota et al., 2013) This upregulation occurs through a specific Toll-like 
receptor called TLR2.(Vinnakota et al., 2013) The group demonstrated in vivo that when 
TLR2 was knocked-down, there were lower levels of MT1-MMP and subsequently 
smaller tumors.(Vinnakota et al., 2013) 
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TAMS AND ANGIOGENESIS 
 
To date, anti-VEGF therapy has proven ineffective in prolonging the survival of 
glioblastoma patients.(Kloepper et al., 2016) VEGF’s role in cancer cells is to recruit new 
blood vessels to the site of the tumor and thereby promote angiogenesis and proliferation 
of the tumor. Angiopoietin-2 (Ang-2) is another angiogenesis-promoter for tumors and 
has been shown to aide tumor cells in recruiting new blood vessels in the presence of 
anti-VEGF therapies.(Kloepper et al., 2016) Ang-2 has also been implicated in recruiting 
TAMs to the site of the tumor that have more M2-like phenotypes.(Kloepper et al., 2016) 
By simultaneously targeting both Ang-2 and VEGF with a dual Ang-2/VEGF-inhibiting 
antibody (A2V), there is an increased survival rate and delayed tumor growth.(Kloepper 
et al., 2016) Along with its anti-angiogenic effects, one of the primary causes of this 
prolonged survival is that the A2V therapy is able to revert the M2 TAM phenotype back 
into an M1 tumor-attacking TAM phenotype.(Kloepper et al., 2016) 
 
Another method by which anti-angiogenic therapies are being combined with a therapy 
against TAMs is by attempting to prevent the recruitment of any TAMs to the tumor site 
in the presence of an anti-angiogenic therapy.(Deng et al., 2017) When given an anti-
angiogenic therapy, the tumor microenvironment becomes hypoxic and recruits TAMs by 
stromal-derived factor (SDF)-1alpha (CXCL-12).(Deng et al., 2017) When given an 
SDF-1alpha inhibitor along with an anti-angiogenic therapy (such as anti-VEGF), there is 
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a significant reduction in the level of TAM recruitment as well as prolonged rodent 
survival as compared to just anti-angiogenic therapy alone.(Deng et al., 2017)  
 
TAMs also serve a tumor-supportive role in the presence of anti-angiogenic 
therapies.(Castro et al., 2017) The anti-angiogenic therapy bevacizumab is a monoclonal 
antibody against VEGF that attenuates tumor progression for only a short duration of 
time before the tumor cells acquire resistance to the therapy.(Castro et al., 2017) The 
primary reason for acquiring this resistance and subsequently leading to tumor 
progression is because the therapy bevacizumab binds and inhibits migration inhibitory 
factor (MIF), which is needed for TAM M1 polarization.(Castro et al., 2017) VEGF also 
naturally increases MIF production in glioma cells so when the cells are treated with 
bevacizumab, VEGF is neutralized and there is therefore a reduction in MIF production 
in the glioma cells.(Castro et al., 2017) This means that there is now a severely decreased 
level of MIF, which allows TAMs to switch to an M2 profile, thereby supporting tumor 
progression even in the presence of the therapy bevacizumab.(Castro et al., 2017) 
 
GBM cells are also able to use microglia for their own tumor progression by releasing 
CSF-1, also called macrophage colony-stimulating factor (MCSF), which causes 
microglia to release insulin-like growth factor-binding protein 1 (IGFBP1) and as a 
result, promote angiogenesis.(Nijaguna et al., 2015) Interestingly, MCSF released by 
tumor cells does not affect M2 polarization.(Nijaguna et al., 2015) This could provide an 
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opportunity for attempting to combine a therapy with a CSF-1R inhibitor to reduce M2 
TAM phenotype along with reducing angiogenesis.   
 
M2 TAMs have further been shown to induce vasculogenic mimicry (VM) through 
activation of cyclooxygenase-2 (COX-2).(Rong et al., 2016) VM is the name of the 
phenomenon given when tumor cells create a new type of vascular system that is 
independent of vascular endothelial cells.(Rong et al., 2016) These tumor cells are able to 
create vascular channels that allow blood to flow through without the need of vascular 
endothelial cells.(Rong et al., 2016) M2 TAMs, particularly those that are activated by 
IL-4, are able to induce VM in glioblastoma tumor cells much more than those tumor 
cells that were not exposed to M2 TAMs (Figure 5).(Rong et al., 2016) M2 TAMs 
induce VM by increasing the amount of COX-2, which has been shown to be elevated in 
GBM.(Rong et al., 2016) When COX-2 is inhibited, the level of VM is significantly 
reduced.(Rong et al., 2016)  
  16 
 
Figure 5: Vasculogenic Mimicry (VM) in the presence of M2 TAMs. Top left – 
Tumor cells without TAMs. No VM. Top right – Tumor cells treated with IL-4 activated 
M2 TAMs. VM seen. Bottom left – Tumor cells treated with non-IL-4 activated M2 
TAMs. Some VM but not as robust as IL-4 activated TAMs. Bottom right – Positive 
control. Figure taken from (Rong et al., 2016).(Rong et al., 2016) 
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TAM AND T CELL INTERACTIONS 
 
Part of the TAM’s supporting role comes via an interaction between CD4 T cells and 
TAMs that cause the CD4 T cells to secrete the immunosuppressive IL-10 and TGF-
beta.(Z. Li, Liu, Guo, & Wang, 2016) Activated TAMs also act as the antigen-presenting 
cells to T cells and interact with one another via MHC Class II molecules.(Graeber, 
Scheithauer, & Kreutzberg, 2002) In high grade glioblastoma, the relative amount of 
MHC Class II antigens is much lower even though there are many more microglia in the 
tissue than in normal brain.(Graeber et al., 2002) Glioblastoma cells are able to 
downregulate expression of MHC II molecules on microglia, and this effect can be 
blocked by treating the culture with an anti-IL-10 antibody.(Taniguchi, Ono, Yoshida, & 
Tanaka, 2000) 
 
A certain subset of T cells function as regulatory anti-inflammatory cells, the usual ones 
being Foxp3+ Tregs and Foxp3- type 1 regulatory (Tr1) cells.(Z. Li et al., 2016) In many 
cancers, Foxp3+ Tregs suppress inflammatory responses by NK cells and other T cells.(Z. 
Li et al., 2016) The Foxp3- Tr1 cells have an unusually high expression level of IL-10 in 
tumors, which serves as an immune-suppressant.(Z. Li et al., 2016) Both CD4+ and 
CD8+ T cells have been found to express high levels of the immuno-supressive IL-10 
cytokine, but there is a relative higher abundance of CD4+ positive T cells expressing IL-
10, particulary those that are Foxp3-.(Z. Li et al., 2016) In normal brain there is 
essentially no IL-10 expressing CD4+ T cells, while there are many of these cells found 
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in the blood and brain of GBM patients.(Z. Li et al., 2016) It has been shown that naïve 
CD4+ T cells can be induced into becoming IL-10-producing Tr1 cells in the presence of 
TAMs alone.(Z. Li et al., 2016) When TAMs are removed from a culture containing 
naïve CD4+ T cells, there is no transformation into IL-10-producing Tr1 cells but as soon 
as these TAMs are replaced back into the culture, these T cells become IL-10-producing 
Tr1 cells.(Z. Li et al., 2016) Once these Tr1 cells are activated by TAMs, the Tr1 cells are 
able to secrete IL-10 and TGF-beta, which both work to suppress anti-tumor 
inflammation.(Z. Li et al., 2016) When CD4+ and Tr1 cells were co-cultured, there was a 
significant decrease in the expression level of TNF-alpha and IFN-gamma, both of which 
are pro-inflammatory, anti-tumor cytokines.(Z. Li et al., 2016) When IL-10 and TGF-beta 
are blocked, there is a sharp increase in the expression of TNF-alpha and IFN-gamma 
CD4+ T cells again.(Z. Li et al., 2016) Activated Tr1 cells are also able to suppress the 
cytotoxic effect of CD8+ T cells thereby providing another reason why anti-tumor T cell 
response in GBM is so low since CD8+ T cells are normally important for killing 
pathogens and cancer cells.(Z. Li et al., 2016) Further work is now needed in this area to 
determine how TAMs induce these naïve CD4+ T cells into becoming immune-
suppressive Tr1 cells, in the hopes that this signaling pathway can also be blocked so that 
T cells may return to their cytotoxic profiles and work on killing the tumor. 
 
Other interactions of TAMs with T cells suppress their anti-tumor function through the 
use of CCL2. CCL2 is a chemokine that is released by TAMs that is able to attract and 
recruit CCR4+ Tregs.(Chang et al., 2016) Level of CCL2 expression in GBM patients is 
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strongly correlated with median survival rate, with higher expression levels of CCL2 
translating to lower median survival.(Chang et al., 2016) Glioma cells, by releasing 
CCL20 and osteoprotegrin, are able to induce TAMs to release CCL2 (Figure 6).(Chang 
et al., 2016) When mice are depleted of CCL2, there is a sharp reduction in the number of 
recruited Tregs at the tumor site.(Chang et al., 2016) The CCL2 receptor, CCR4, which is 
found on Tregs can also be targeted with a small molecule that acts as an antagonist in 
order to suppress Treg recruitment to tumor site.(Chang et al., 2016) Administering this 
small molecule increased the survival in murine models, showing a promising avenue to 
pursue in combination with other therapies.(Chang et al., 2016) 
 
 
Figure 6: GBM cells, TAM, and T Cell Interactions. Taken from (Chang et al.,  
2016)(Chang et al., 2016) 
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TAMs are also able to suppress T cells through the use of the co-stimulatory molecule 
B7-homologue (B7-H1).(Bloch et al., 2013) Circulating monocytes in peripheral blood 
and TAMs in GBM patients have an increased level of expression of B7-H1, particularly 
in tumor tissue, as compared to healthy control subjects.(Bloch et al., 2013) When T cells 
are co-cultured with macrophages from peripheral blood from a GBM patient, there is a 
high rate of T cell apoptosis, implying that the macrophages are in part responsible for 
the decreased T cell response seen in GBM (Figure 7).(Bloch et al., 2013) When 
peripheral blood monocytes from control patients are co-cultured with GBM cells and 
GBM patient media, there is a significant increase in the B7-H1 expression level found 
on the monocytes.(Bloch et al., 2013) This implies that a secreted molecule from the 
GBM cells is responsible for the increase in B7-H1 levels seen in GBM TAM 
populations.(Bloch et al., 2013) The secreted molecule is believed to function by 
increasing the TAM’s sensitivity to its own IL-10 production by increasing the level of 
IL-10R found on TAM cell surface.(Bloch et al., 2013) This increased IL-10 production 
is sufficient to increase the B7-H1 levels seen on TAMs.(Bloch et al., 2013) This 
combination of increased IL-10 secretion and sensitivity along with increased B7-H1 
levels on TAMs causes an increase in T cell apoptosis.(Bloch et al., 2013) However, 
TAMs that are treated only with IL-10 to increase their B7-H1 expression do not cause as 
high of a level of T cell apoptosis as they do when co-cultured with GBM media (Figure 
8).(Bloch et al., 2013) This implies that there may in fact be more than one secreted 
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stimulatory factor from GBM that increases the production of B7-H1 on TAMs and is not 
solely an IL-10 based role.(Bloch et al., 2013)  
 
Figure 7: T Cell Apoptosis in Presence of Peripheral Blood Monocytes of GBM 
Patients. One healthy control subject along with 3 GBM patient samples. Figure taken 
from (Bloch et al., 2013)(Bloch et al., 2013) 
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Figure 8: T Cell Apoptosis in Presence of Monocytes Exposed to IL-10 or GBM 
Media. Monocytes that were exposed to IL-10 alone as opposed to those exposed to 
GBM conditioned media had much less effect on T cell apoptosis, implying that it is not 
the increase in IL-10 alone that GBM cells use to increase the apoptotic-inducing nature 
of TAMs. Figure taken from (Bloch et al., 2013)(Bloch et al., 2013) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  23 
REVERSING M2 TO M1 POLARIZATION 
 
A hallmark of TAMs in GBM has been an increased level of M2 TAMs in relation to M1 
TAMs. Since higher grade gliomas are correlated with higher M2 TAM density and since 
M2 TAMs are immune-suppressive in nature, much research is being done on how to 
convert these M2 TAMs into anti-tumor M1 TAMs in hopes of slowing tumor 
progression.  
 
It has been shown that following tumor resection of GBM, it is possible to prolong 
survival in vivo by locally injecting anti-CD47 antibodies to the lesion site.(H. Zhu et al., 
2017) CD47 is a cell surface protein expressed on tumors that interacts with macrophages 
via the signal regulatory protein-alpha (SIRP-alpha).(H. Zhu et al., 2017) When CD47 
interacts with SIRP-alpha, it inhibits the macrophage’s phagocytotic ability, thereby 
bypassing the M1 TAM phagocytotic phenotype and allowing the tumor cell to 
survive.(H. Zhu et al., 2017) The local CD47 antibody injection has been shown to 
function and slow the progression of tumor in rodent models even weeks after tumor 
implantation, insinuating that this injection could provide a promising opportunity to 
extend survival even when the tumor is fully grown (Figure 9).(H. Zhu et al., 2017) A 
primary reason that anti-CD47 antibody treatment works to effectively shrink tumor size 
and slow growth is because many of the M2 macrophages are either reverted to an M1 
phenotype and are induced to start phagocytosis of tumor cells.(Zhang et al., 2016) 
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Figure 9: Local Injection of Anti-CD47 Antibody with Tumor Resection. Debulking 
– tumor resection. Tumor is smallest with a combination of resection and anti-CD47 
antibody treatment immediately following resection. Figure taken from (Zhu et al., 
2017)(H. Zhu et al., 2017) 
 
It has been shown that glioma stem cells (GSCs) are able to influence whether TAMs will 
express p-STAT1 or p-STAT3.(Wu et al., 2010) M1 TAMs normally express p-STAT1 
but when they are reverted into M2 TAMs, they downregulate their expression of p-
STAT1 and upregulate their expression of p-STAT3 (Figure 10).(Wu et al., 2010) It is 
known that in GBM cells, STAT3 is constitutively active.(Lo, Cao, Zhu, & Ali-Osman, 
2008) When M1 TAMs are co-cultured with GBM media, the relative amount of p-
STAT1 drops significantly, indicating a shift toward an M2 phenotype.(Wu et al., 2010) 
These TAMs will now secrete IL-10 and TGF-beta, which are known immune-
suppressants.(Wu et al., 2010) When pSTAT3 is inhibited, however, there is a decrease in 
TAM release of IL-10, suggesting that the increase in p-STAT3 levels seen in TAMs and 
GBM cells is in part responsible for the immune-suppressive phenotype seen in 
TAMs.(Wu et al., 2010) Inhibition of STAT3 also reverses the TAMs non-phagocytic 
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profile back into a phagocytic one.(Wu et al., 2010) MIC-1 released by GSCs cells has 
also been shown to give TAMs a more M2-like phenotype by suppressing their ability for 
phagocytosis as well inducing them to secrete immune-suppressive cytokines like IL-10 
and TGF-beta.(Wu et al., 2010) MIC-1 is also able to decrease the expression level of p-
STAT1 seen typically in M1 TAMs but inhibition of GSC production of p-STAT3 does 
not attenuate their release of MIC-1, showing that MIC-1 does not directly rely on p-
STAT3 for its activation.(Wu et al., 2010) IL-6, which is released by M2 TAMs in GBM, 
also activates STAT3 and by doing so, increases the expression of MMP-9 and VEGF, 
which contribute to tumor growth.(Eder & Kalman, 2015) 
 
 
Figure 10: Proposed Interaction Between Glioma Stem Cells and TAMs. Many of 
these effects of GSCs are thought to be due to increased STAT3 expression. Figure taken 
from (Wu et al., 2010)(Wu et al., 2010) 
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Another treatment method that has been found to reverse M2 polarization back into M1 
polarization is the use of chlorogenic acid (CHA).(Xue et al., 2017) CHA is able to slow 
the progression of tumors both in vivo and in vitro by activating the STAT1 pathway, 
which is necessary for M1 polarization of TAMs.(Xue et al., 2017) CHA also slows 
tumor progression by inhibiting TAM M2 polarization by suppressing the STAT6 
pathway, which is necessary for proper M2 polarization.(Xue et al., 2017) 
 
It has also been demonstrated that microglia can be switched to a more M1-like 
phenotype with anti-tumor properties by stimulating its Toll-like receptor 3 with an 
agonist called polyinosinic:polycytidylic acid (abbreviated poly(I:C)).(Kees et al., 2012) 
After treatment with poly (I:C), microglia began secreting toxic factors that slowed 
proliferation of GBM cells without affecting any neighboring neurons or glial cells.(Kees 
et al., 2012) 
 
One group found that S-nitrosylation of microglial caspase-3 induced by glioma cells 
helped shift the microglia to a more tumor-supportive role.(Shen et al., 2016) Their 
evidence showed that glioma cells inhibited microglial basal caspase-3 activity and that 
the microglia that were found in the tumor were significantly less abundant in cleaved 
caspase-3 than microglia on the periphery of the tumor.(Shen et al., 2016) The group also 
showed that a knockdown of caspase-3 promoted a shift in the microglia toward a tumor-
supportive role.(Shen et al., 2016)  
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TAMS WITH VIRAL AND DRUG THERAPIES 
 
It is known that when microglia derived from non-glioma patients is combined with brain 
tumor-initiating cells (BTICs), these microglia mitigated the BTICs sphere-forming 
capacity.(Sarkar et al., 2014) The antifungal drug amphotericin B (AmpB) was shown to 
activate microglia and prevent sphere-formation.(Sarkar et al., 2014) 
 
Microglia and macrophages also play a role in the efficacy of oncolytic herpes simplex 
virus (oHSV) therapy.(Meisen et al., 2015) When oHSV therapy is introduced, microglia 
and macrophages infiltrate in large numbers and secrete TNF-alpha, which causes 
apoptosis of cells containing oHSV and decreases oHSV replication.(Meisen et al., 2015) 
When this pathway is blocked by a TNF-alpha inhibitor, it significantly enhances virus 
replication.(Meisen et al., 2015) However, treatment with TNF-alpha inhibitor would 
most likely not be a suitable approach because of its deleterious effects on TAM 
polarization. TNF-alpha is an important cytokine for M1 polarization and inhibiting it 
may only increase tumor progression.  
 
It has also been shown that treatment with an immunosuppressive cytokine, TGF-beta, 
which suppresses the innate immune system (primarily NK cells and microglia), causes 
better oncolytic virus, particularly oHSV efficacy.(Han et al., 2015) Administration of 
this TGF-beta prior to oHSV therapy to silence the innate immune system increased 
survival rate and decreased tumor growth, through preventing early clearance of the 
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virsus.(Han et al., 2015) However, a major problem of treatment with TGF-beta is that it 
is an immuno-suppressant and discourages M1 polarization of TAMs and has a negative 
effect on anti-tumor characteristics of the immune system, thereby making it more likely 
for GBM cells to evade immune detection. While these treatments may promote better 
virus replication, their overall effects may cause more harm than good because of its 
deleterious effects caused by immune-suppression and silencing M1 TAMs even further. 
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MAKERS OF MICROGLIA, MACROPHAGES, AND M1/M2 
 
While there are many markers used to stain for TAMs, some are more specific than 
others and only mark certain subsets of TAMs, like for example only those with M1 
characteristics. Therefore, it is useful to consolidate the most common and most accurate 
antibodies used when staining for these antibodies so as to avoid confusion and better 
elucidate which TAMs are present in a particular area.  
 
Several markers are able to stain both microglia and macrophages and are therefore not 
entirely specific. Iba1, for instance, is a common maker that will show both.(Shen et al., 
2016)(Nakamura et al., 2013) CD68 is also another very common marker used to stain 
both macrophages and microglia.(Hambardzumyan et al., 2016) Other common markers 
for microglia and macrophages are F4/80 and CD11b.(Prinz, Priller, Sisodia, & 
Ransohoff, 2011)(Parney, Waldron, & Parsa, 2009a) 
 
The primary method by which to distinguish monocyte-derived macrophages from 
microglia is that microglia are CD45 low and invading monocytes are CD45 high.(Badie 
& Schartner, 2000) (Parney et al., 2009a) For a more thorough differentiation, 
CD11b+/CD45 low marks for microglia while CD11b+/CD45high/Ly6G-/Ly6C high 
marks invading macrophages.(Mildner et al., 2007) (Szulzewsky et al., 2015) Microglia 
express high levels of CX3CR1, CD11b, and F4/80 but low levels of CD45 and no 
CCR2. Relative CCR2 and CD45 expressions are the main differences between microglia 
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and macrophages.(Mildner et al., 2007) Another way to distinguish monocyte-derived 
macrophages from resident microglia is by comparing the relative levels of CX3CR1 to 
CCR2 via flow cytometry.(Mizutani et al., 2012) The microglia profile shows a ratio of 
CX3CR1hi/CCR2lo in both inflamed and adult naïve microglia, while monocyte-derived 
macrophages show a relatively lower level of CX3CR1 and higher level of CCR2 as 
compared to the resident microglia.(Mizutani et al., 2012) Another microglia-specific 
marker is the purinergic receptor P2Y12 (P2RY12).(C. Zhu et al., 2017) P2RY12 has 
been found to stain CD68+ cells but not CD45+ cells, leading to the conclusion that 
P2RY12+ cells are not myeloid-derived in origin but instead represent the resident 
microglia population.(C. Zhu et al., 2017) P2RY12 can be expressed either in the 
cytoplasm of the cell or in the nucleus, with expression in the latter correlating to a more 
M2-like phenotype (Figure 11).(C. Zhu et al., 2017) Lower grade tumors are associated 
with P2RY12 expression in the cytoplasm (M1-like phenotype).(C. Zhu et al., 2017) 
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Figure 11: P2RY12 Expression Location vs M2 Markers. Left column represents 
staining for cytoplasmic P2RY12 staining along with the M2 markers (CD163 and 
CD204) – no co-staining. Right column represents staining for nuclear P2RY12 staining 
along with M2 markers – robust co-staining. Figure taken from (Zhu et al., 2017)(C. Zhu 
et al., 2017) 
 
It has been shown that there is a higher ratio of invading macrophages than resident 
microglia in glioma.(Parney, Waldron, & Parsa, 2009b) However, another study has 
shown that there may in fact be a higher ratio of microglia than macrophages and that the 
microglia may in fact upregulate their CD45 expression, which makes it appear as though 
it were a monocyte-derived macrophage.(Müller, Brandenburg, Turkowski, Müller, & 
Vajkoczy, 2015)  
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The most common markers used to differentiate M1 from M2 are as follows: M1 (iNOS, 
IL-1 beta, TNF-alpha, MHC Class II, and CXCL10) and M2 (Arg-1, CD206, 
CD163).(Umemura et al., 2008)(Komohara et al., 2008) Arg-1 and iNOS are often used 
for M2 and M1 TAMs respectively because those types of macrophages give rise to those 
mediators.(Lisi et al., 2017) iNOS is a proinflammatory, tumor-suppressive mediator 
while Arg-1 is a tumor-supporting, anti-inflammatory mediator.(Lisi et al., 2017) iNOS 
M1 TAMs are also found in higher abundance at the periphery of the tumor, suggesting 
that the further into the tumor that the TAM goes, the more likely it is to be affected by 
the tumor microenvironment and reverted to an M2 phenotype. Both iNOS and Arg-1 
downregulate each other and use L-arginine as a substrate, which is one reason why 
either M1 or M2 TAMs tend to dominate a specific tissue.(Lisi et al., 2017)  
 
Another group has recently shown markers that are potentially more specific than the 
ones commonly used and include M1 (CD38+, Fpr2, Gpr18) and M2 (Egr2, c-
myc).(Jablonski et al., 2015) CD38+ labeled most in vitro M1 macrophages (upregulated 
30-fold in M1 macrophages).(Jablonski et al., 2015) Formyl peptide receptor 2 (Fpr2) 
and G-protein coupled receptor 18 (Gpr18) were upregulated 8-fold in M1 macrophages 
– another marker for M1 macrophages.(Jablonski et al., 2015) All of these genes were 
downregulated 2 to 25 fold in M2 macrophages. Early growth response protein 2 (Egr2) 
labels most M2 macrophages.(Jablonski et al., 2015) c-myc is 3-fold increased in M2 
macrophages while 2-fold decrease in M1 macrophages, making it another marker for 
M2.(Jablonski et al., 2015) 
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Morphologically, microglia can be separated into three different states: ramified (resting), 
activated, and phagocytotic (ameboid) (Figure 12).(Sasaki, 2016) 
 
 
Figure 12: Microglia Subtypes and Marker Expression. Taken from (Sasaki, 
2016)(Sasaki, 2016) 
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Macrophages Microglia M1 M2 Macrophage+Microglia 
CD45 high CD45 low CD38+ Egr2 Iba1 
CCR2+ CCR2- Fpr2 c-myc CD68 
Ly6G- CX3CR1hi Gpr18 Arg-1 CD11b 
Ly6Chi CCR2lo iNOS CD206 F4/80 
 
P2RY12 IL-1beta CD163 
 
  
CD11c CD204 
 
  
CXCL10 
  TNF-alpha 
  MHC II   
Table 1: Summary of TAM Markers. 
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DISCUSSION AND CONCLUSION 
 
Since TAMs comprise nearly 30% of the tumor mass in GBM and are continually being 
shown in studies as an essential component to tumor progression, TAMs in the tumor 
microenvironment are an attractive target for therapies against GBM. As the role of 
TAMs are elucidated, more potential avenues for therapies arise and different 
combinations can be tested and applied. There are five major ways to interfere with 
TAM’s tumor-supportive role: 1) Interfere with the recruitment of TAMs by GBM cells 
2) Interfere with the angiogenesis role of TAMs 3) Interfere with M2 polarization and 
revert to M1 polarization 4) Interfere with TAM suppression of T cell immunity and 5) 
Interfere with GBM mobility. Each of these methods shows promising results and the 
most effective TAM-based therapies would most likely involve a combination of all five 
approaches. 
 
Perhaps the most promising approach to interfering with TAM recruitment is by using a 
combination of a CSF-1R inhibitor and an IGF-1R inhibitor. The combination of 
inhibitors greatly prolongs the survival of rodent models because it slows the process of 
tumor resistance to therapy.(Quail et al., 2016) Combining these two therapies along with 
an inhibitor to GM-CSF could prove even more beneficial and is worth pursuing. GM-
CSF is greatly overexpressed in GBM patients and its depletion causes an increase in 
mouse survival and a decrease in angiogenesis, thereby interfering with both recruitment 
and angiogenesis.(Sielska et al., 2013) Studies could combine a GM-CSF inhibitor with 
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CSF-1R and IGF-1R inhibitors in vivo to determine if this combination leads to better 
survival outcomes and to determine any levels of potential toxicity. These inhibitors 
could also be combined with an inhibitor of periostin, which is actively secreted by GBM 
cells and is in part responsible for recruiting TAMs to the tumor site.(Zhou et al., 2015) 
When periostin is depleted, the tumor shrinks in size and there is a sharp decrease in the 
relative levels of M2 TAMs compared to M1 TAMs.(Zhou et al., 2015) Considering that 
EGFR is the most common mutation in GBM cells and that its inhibition reduces TAM 
infiltration, it should be included in these combination therapies as a way to slow TAM 
infiltration.(Coniglio et al., 2012) A further experiment should also look into the role of 
MCP-3 and how it is involved in TAM recruitment in relation to CCL2 (MCP-1) since 
CCL-2 has generally been considered the more important of the two before a recent study 
has called this into question. Once determined, inhibitors to either of these molecules 
could be added in conjunction for a therapy against TAM recruitment that may prove 
much more effective than any of these treatments alone.  
 
In regards to angiogenesis, a combination therapy that uses A2V antibody may prove to 
be the most promising of approaches. Not only does A2V treatment reduce angiogenesis 
and thereby shrink tumor size, it also reverts M2 TAMs back into M1 TAMs making it 
that much more of an anti-tumor environment.(Kloepper et al., 2016) This A2V antibody 
could prove to be even more potent in combination with an SDF-1alpha inhibitor, which 
is normally responsible for TAM recruitment in the presence of anti-angiogenic therapies 
(the TAM recruitment is triggered by the hypoxic environment), because adding this 
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inhibitor would likely extend mouse survival because less M2, tumor-supportive TAMs 
would be recruited to the tumor site and would therefore make anti-angiogenic therapies 
even more effective. This decrease in M2 TAMs by the use of an SDF-1alpha inhibitor 
could further mitigate one of the angiogenic roles that M2 TAMs play by increasing 
COX-2, which increases vasculogenic mimicry (VM) by GBM cells.(Rong et al., 2016) 
Since GBM cells do not need endothelial cells to make blood vessels and can do so by 
COX-2 supplied by M2 TAMs, inhibiting their recruitment with an SDF-1alpha inhibitor 
could prove much more effective in slowing tumor growth. A COX-2 inhibitor could also 
be added to this cocktail of anti-angiogenic therapies to prevent this VM effect in any 
remaining M2 TAMs that remain even in the presence of A2V and SDF-1alpha 
treatments.  
 
A promising approach to interfering with TAM/T-cell interactions is by using an anti-IL-
10 antibody in addition to discovering how TAMs are able to activate the immune-
suppressive Tr1 cells and suppressing that communication. Once it is determined how 
TAMs are able to induce Tr1 cells to begin secreting the immune-suppressive cytokine 
IL-10, this communication can be inhibited and added in conjunction with anti-IL-10 
antibody. The other attractive prospect of using an anti-IL-10 antibody is that its use is 
able to increase the amount of MHC Class II antigen presentation to other T cells, thereby 
making it more likely that T cells will have a more anti-tumor response. The immune-
suppressive Tregs are also found in high densities in GBMs and have proven to be an 
effective target at slowing tumor growth.(Z. Li et al., 2016) By either inhibiting CCL2 
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release from TAMs or by inhibiting the CCL2 receptor found on Tregs (CCR4) with a 
small molecule, there is a significant attenuation of tumor growth and Treg recruitment to 
the tumor site.(Z. Li et al., 2016) Another interaction to inhibit is the B7-H1 interaction, 
which causes T cells to undergo apoptosis.(Bloch et al., 2013) By preventing this 
interaction, more cytotoxic, anti-tumor T cells can respond to the tumor and slow its 
progression. By using a combination of these approaches to inhibit T cell-TAM 
interactions, survival outcomes may prove to increase. 
 
To help promote M1 polarization and phagocytic phenotype of TAMs, the most 
promising treatments seem to be an anti-CD47 antibody and a STAT3 inhibitor. STAT3 
activation is needed for M2 polarization and when it is inhibited, the TAMs will begin to 
revert back to a phagocytic nature and will stop producing the immune-suppressant IL-
10.(Wu et al., 2010) This STAT3 target is also an attractive target because it is already 
known that STAT3 is abnormally constitutively active in GBM cells and is correlated 
with a high M2 density.(Wu et al., 2010) The anti-CD47 treatment functions likewise to 
restore the TAM’s phagocytic ability. This anti-CD47 treatment is given post tumor 
resection and could therefore be combined with another treatment like the STAT3 
inhibitor. Combining CHA treatment with the aforementioned treatments may also prove 
beneficial since CHA activates the STAT1 pathway, which is needed for M1 
polarization.(Xue et al., 2017) Using CHA would activate TAMs into an M1 phenotype, 
anti-CD47 antibody treatment would increase TAM phagocytic ability post-tumor 
resection, and the STAT3 inhibitor would prevent TAMs becoming M2 polarized and 
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allow them to be phagocytic instead. A combination of all these treatments would 
perhaps be much better than any single treatment on its own since all of these treatments 
would take advantage of a different pathway in order to make sure as many TAMs are 
phagocytic and M1-like as possible, therefore leading to smaller tumors and longer 
survival rates.  
 
Since a major reason for GBM’s high mortality rate is because of its ease of mobility 
around the brain, a cocktail of therapies should include a therapy that targets and inhibits 
GBM mobility. TAMs play a critical role in aiding GBM mobility by providing matrix 
metalloproteinases (MMPs), which allow GBM cells to freely move and travel 
throughout the brain. This means that once a tumor is resected, other tumors will 
regenerate in different areas of the brain leading ultimately to mortality. Using a 
combination of therapies to prevent GBM migration should extend survival and several 
different routes targeting this GBM-TAM interaction can be approached. Since MMP9 is 
one of the primary MMPs responsible for GBM migration that is secreted by TAMs, 
using an NHE1 inhibitor to prevent the release of MMP9 along with an STI1 antibody 
that also blocks MMP9 activity could prove much more effective than either treatment 
alone.(W. Zhu et al., 2016) (A. C. C. da Fonseca et al., 2012) Targeting MMP9 along 
with MT1-MMP via a TLR2 inhibitor should also limit tumor progression even further 
than either one alone since inhibiting TLR2 inhibits another MMP that contributes to 
GBM migration.(Vinnakota et al., 2013) 
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Although much has been discovered about the relationship between TAMs and GBM 
cells, much more work needs to be done to elucidate aspects of the communications 
between the two sets of cells. TAMs are an especially attractive target for GBM therapy 
because unlike GBM cells, they are not prone to mutations and resistance in the same was 
as GBM cancer cells are. Their relationship with GBM cells seems to be primarily tumor-
supportive and critical for tumor growth, angiogenesis, and migration. Targeting all 
aspects of the TAM/GBM relationship as discussed in the aforementioned sections by a 
cocktail of therapies will likely be the most effective route in prolonging patient survival 
and slowing tumor progression. Future studies into TAMs in GBM should focus on 
illuminating their precise relationship and importantly attempting to combine different 
therapies together to slow and prevent tumor resistance. An effective combination of 
therapy against TAMs in GBM will likely involve anti-angiogenic therapies, reverting to 
TAMs to a phagocytic M1 polarized state, preventing TAM recruitment, inhibiting the 
TAM/T cell immune-suppressive relationship, and inhibiting the TAM’s induction of 
GBM migration.  
  
  41 
 
Figure 13: Summary of Tumor Microenvironment. Figure taken from (Dunn-Pirio et 
al., 2016)(Dunn-Pirio & Vlahovic, 2017) 
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Figure 14: Summary of Stimulatory and Inhibitory Factors Between GBM Cells 
and Immune Cells. Dark black lines indicate stimulatory effects while light grey lines 
indicate inhibitory effects. Taken from (Eder et al., 2015)(Eder & Kalman, 2015) 
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